Wall Street Analysts Predict Omnicell (OMCL) May Rise by 30.93%: Important Insights Before You Invest
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 27 2025
0mins
Source: NASDAQ.COM
Stock Performance and Analyst Predictions: Omnicell (OMCL) shares have risen 24% recently, with a mean price target of $48 suggesting a potential upside of 30.9%, although estimates vary widely among analysts.
Skepticism Towards Price Targets: Investors should approach price targets with caution, as they can often be misleading due to analysts' potential biases and business incentives, despite some agreement indicating a possible stock price movement.
Earnings Estimate Revisions: Analysts have shown increasing optimism about Omnicell's earnings, with a 17.5% increase in the Zacks Consensus Estimate, which historically correlates with positive stock price movements.
Investment Strategy Considerations: While the consensus price target may not be entirely reliable, the direction it suggests, combined with strong earnings revisions, could provide a useful guide for investors considering OMCL.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OMCL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OMCL
Wall Street analysts forecast OMCL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for OMCL is 54.20 USD with a low forecast of 46.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 49.960
Low
46.00
Averages
54.20
High
63.00
Current: 49.960
Low
46.00
Averages
54.20
High
63.00
About OMCL
Omnicell, Inc. is a provider of medication management solutions and adherence tools for health systems and pharmacies. The Company is focused on transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care through a portfolio of robotics, smart devices, intelligent software, and services. Its point of care automation solutions is designed to improve clinician workflows in patient care areas of the healthcare system, such as nursing units, patient wards, operating rooms, and emergency departments. The Company’s XT Series automated dispensing systems for medications and supplies, which are used in nursing units and other clinical areas of the hospital, are designed to support workflows specific to each area of the hospital, with various software and hardware options. For the operating room, the Company also offer specialized automated dispensing systems.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Mixed on Thursday as Tech Sector Faces Pressure
- Market Volatility: The S&P 500 Index closed up 0.01% while the Dow Jones Industrial Average rose 0.55%, and the Nasdaq 100 fell 0.57%, indicating mixed market performance amid weakness in tech stocks.
- Economic Data Impact: Initial jobless claims in the US rose by 8,000 to 208,000, lower than the expected 212,000, suggesting a strong labor market that could influence Fed policy in a hawkish direction.
- Military Spending Expectations: President Trump announced plans to increase the US military budget by 50% to $1.5 trillion by 2027, leading to a rally in defense stocks, with AeroVironment rising over 8%.
- Energy Market Rebound: Energy producers surged as WTI crude oil prices rose by more than 3%, with APA Corp leading gains in the S&P 500, up over 8%.
Continue Reading
Trump Plans to Increase Military Spending to $1.5 Trillion
- Military Budget Increase: President Trump plans to ramp up U.S. military spending by about 50% to $1.5 trillion by 2027, which is expected to significantly boost growth in the defense sector and enhance market confidence in related companies.
- Defense Stocks Rally: Following this announcement, AeroVironment (AVAV) shares surged over 8%, and Huntington Ingalls Industries (HII) rose more than 7%, reflecting investor optimism regarding increased defense spending.
- Market Reaction: Despite weakness in chipmakers and software companies, the strong performance of defense stocks helped contain broader market declines, indicating a divergence in capital flows and investor sentiment across sectors.
- Economic Data Impact: U.S. economic data showed initial jobless claims rose to 208,000, lower than the expected 212,000, suggesting a robust labor market that could influence the Federal Reserve's monetary policy direction.
Continue Reading